Cited by 1,192Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCancer Genomics and Diagnostics

The DOI matches its Crossref record; 149 of the 151 references it cites were found in a registry or an index.

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Open access

Jardim, Denis L., Goodman, Aaron, de Melo Gagliato, Debora, Kurzrock, Razelle·2021·Cancer Cell

DOI 10.1016/j.ccell.2020.10.001PMC PMC7878292

Open this paper in CoChat — free account Open PDF

Abstract

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cells. To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment by enabling T cell reactivation; however, response biomarkers are required, as most patients do not benefit. Higher TMB results in more neo-antigens, increasing chances for T cell recognition, and clinically correlates with better ICI outcomes. Nevertheless, TMB is an imperfect response biomarker. A composite predictor that also includes critical variables, such as MHC and T cell receptor repertoire, is needed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.10.001

Cites

149 of 149 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849

Flagged first, then by citations

Show all 151 references

2 of the 151 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Galsky, 2017, Impact of tumormutation burden on nivolumab efficacy in secondline urothelial carcinoma patients: exploratory analysis of the phase II checkmate 275 study, Ann. Oncol., 28, v295, 10.1093/annonc/mdx371.003 · DOI

Sorted by citations

Items 801–900 of 1,000

Building a Risk Scoring Model for ARDS in Lung Adenocarcinoma Patients Using Machine Learning Algorithms
Hong, E., Sun, Y., Qin, Y., Zhao, W., Qin, Y., Li, X., & Zhang, L. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70280 · Cited by 2
Prediction of prognosis, efficacy of lung adenocarcinoma by machine learning model based on immune and metabolic related genes
Xue, C., Dai, Y., Li, G.-L., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-024-01515-x · Cited by 2
Construction of a disulfidptosis-associated lncRNA signature to predict prognosis in bladder cancer
Wang, J., Zheng, Q., Jian, J., Chen, Z., Liu, X., Wan, S., & Wang, L. (2024) · Translational Andrology and Urology · doi:10.21037/tau-24-431 · Cited by 2
NFATC2 target gene signature correlates with immune checkpoint blockade resistance in melanoma
Lawal, B. (2025) · American Journal of Cancer Research · doi:10.62347/eyml2689 · Cited by 2
A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance
Fu, C., Sun, L., Feng, C., Zhou, T., & Bi, Y. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1464578 · Cited by 2
“Higher somatic TMB was previously thought to be associated with better survival in patients treated with immune checkpoint inhibitors since higher TMB promotes more production of neoantigens which could be recognized by T cells (81).”
Integrating transcriptomics and scPagwas analysis predicts naïve CD4 T cell-related gene DRAM2 as a potential biomarker and therapeutic target for colorectal cancer
Feng, R., Li, X., Li, B., Luan, T., He, J., Liu, G., & Yue, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-13731-x · Cited by 2
“…in-depth analysis of various genetic abnormalities, including single nucleotide variations, deletions, gene fusions, and copy number variations [37], it aids in revealing the heterogeneity of tumors, predicting treatment responses, monitoring disease progression, and the development of drug…”
Unveiling the oncogenic role of SLC25A13: a multi-omics pan-cancer analysis reveals its impact on glioma progression
Wu, W., Liu, S., Ren, H., Rao, Y., Nie, J., Wei, K., & Jiang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03696-z · Cited by 3
“Tumor mutational burden and microsatellite instability are considered powerful predictors of immunotherapy response [40, 41].”
Specific Genetic Mutations Impact Chemotherapy Resistance and Therapeutic Efficacy of Oncolytic Viruses in Ovarian Cancer
Cudmore, A. O., Rodriguez, G. M., Maranda, V., Boroujeni, S. F., Murshed, H., Macdonald, E. A., Grondin, M., Garson, K., Matuszewska, K., Diallo, J., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0906 · Cited by 2
A prognostic model based on autophagy-and senescence-related genes for gastric cancer: implications for immunotherapy and personalized treatment
Chen, S., Han, X., Lu, Y., Wang, S., Fang, Y., Leng, C., Sun, X., Li, X., Qiu, W., & Qi, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1509771 · Cited by 2
Analysis of Multiple Programmed Cell Death Patterns and Functional Validations of Apoptosis-Associated Genes in Lung Adenocarcinoma
Peng, Y., Jia, N., Wang, J., Dong, S., Li, S., Qin, W., Shi, H., & Liu, K. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-17224-w · Cited by 2
“27,28 Additionally, Gungabeesoon et al. 29 proposed a significant role for neutrophils in LUAD immunotherapy.”
Construction of a tumor immune microenvironment-related risk scoring model for prognosis of hepatocellular carcinoma
Li, X., Qin, Z., Chen, H., Chen, D., Alimu, N., Li, D., Cheng, X., Yan, Q., Zhang, L., Liu, X., et al. (2025) · International Journal of Immunopathology and Pharmacology · doi:10.1177/03946320251333975 · Cited by 2
“Some studies 36,37 suggest that high somatic mutation burden can result in the expression of neoanti-gens on cancer cells, potentially rending the tumor more visible to the immune system, increasing the likelihood of an anti-tumor immune response.”
A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer
Kobayashi, D., Kosumi, T., Lam, Q. L. K., Fujita, S., Hijikata, Y., Takeda, K., Narita, T., Yamashita, N., Richard, G., Groot, A. S. D., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1609116 · Cited by 2
Spotlight on FAM72B: Pan-Cancer Expression Profiles and Its Potential as a Prognostic and Immunotherapeutic Biomarker
Chu, A., & Wang, Y. (2025) · Genes · doi:10.3390/genes16101140 · Cited by 2
Personalized cancer immunotherapy
Kumar, A., Weller, K. P., & Vilgelm, A. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00012-7 · Cited by 3
Comprehensive Analysis of the Potential Immune-Related Biomarker ATG101 that Regulates Apoptosis of Cholangiocarcinoma Cells After Photodynamic Therapy
Zhang, Z., Wang, K., Huang, Y.-P., Jin, C., Jiang, H., Xiong, L., Chen, Z.-Y., Wen, Y., Liu, Z.-T., & Mo, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.857774 · Cited by 2
“It was concluded that targeting STAT5-and STAT6-related signalling pathways can inhibit the proliferation of CRC cells and induce CRC cell apoptosis (Jiang et al., 2019), and Dong suggested that STAT5A, STAT5B and STAT6 expression may be potential prognostic markers of hepatocellular carcinoma…”
Background
A novel risk model based on immune response predicts clinical outcomes and characterizes immunophenotypes in triple-negative breast cancer.
Lu, X., Gou, Z., Yu, L., & Bu, H. (2022) · PubMed Central · Cited by 2
Comprehensive genomic profiling of a metastatic small cell lung carcinoma with a complete and long-term response to atezolizumab: A case report
Tomić, K., Križanac, D. K., Skenderi, F., Krpina, K., Bilic, A. C., Galić, K., Gatalica, Z., & Vranić, S. (2023) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2023.101920 · Cited by 2
Fatty Acid Metabolism-Related lncRNA Prognostic Signature for Serous Ovarian Carcinoma
Ye, L., Jiang, Z., Zheng, M., Pan, K., Lian, J., Ju, B., Liu, X., Tang, S., Guo, G., Zhang, S., et al. (2024) · Epigenomics · doi:10.2217/epi-2023-0388 · Cited by 2
Identification of nomogram associated with durable clinical benefit gene for advanced non-small cell lung cancer with sensitivity to responsive to immunotherapy
Wang, L., Chu, X., Yu, X., & Su, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e27801 · Cited by 2
Construction and validation of a prognostic signature based on anoikis-related lncRNAs in lung adenocarcinoma
Dong, X., Shao, C., Xu, S., Tu, J., Xu, W., Chen, D., & Tang, Y. (2024) · Aging · doi:10.18632/aging.205905 · Cited by 2
Clinical and molecular impacts of tumor mutational burden in histological and cytological specimens from cancer patients
Li, L., Chen, C., Liu, C., Niu, L. N., & Pan, C. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-358 · Cited by 2
“Immune cells gradually decrease in quantity and become defective in the process of aging (5), and compared to that in elderly patients, the predictive ability of TMB for ICI is better in young patients with NSCLC (38).”
BackgroundInfluential
Therapeutic Interruption of T Cell Development Generates High-Affinity T Cells That Escape Exhaustion and Improve Cancer ImmunotherapyPreprint
Dhuey, E., Oldridge, O., Ravishankar, R., Dada, H., Yu, Y., Anderson, M. S., & Minn, A. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.19.476935 · Cited by 2
“The number of somatic mutations (tumor mutational burden) positively correlates with both neoantigen load and with ICB response, and may account for up to 55% of the difference in response rates between cancer subtypes (Jardim et al., 2021).”
Background
SPP1 is expected to be a biomarker for predicting prognosis and immunotherapy efficacy in penile cancer patientsPreprint
Zou, Y., Tan, X., Yuan, G., Tang, Y., Wang, Y., Yang, C., Luo, S., & Yao, K. (2022) · Research Square · doi:10.21203/rs.3.rs-1934794/v1 · Cited by 2
Spatial assessment of stromal B cell aggregates predicts response to checkpoint inhibitors in unresectable melanomaPreprint
Smithy, J. W., Peng, X., Ehrich, F. D., Moy, A. P., Yosofvand, M., Maher, C. A., Aleynick, N., Vanguri, R. S., Zhuang, M., Lee, J., et al. (2024) · medRxiv · doi:10.1101/2024.08.09.24311758 · Cited by 2
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape
Xue, X., Wang, J., & Ye, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01307-1 · Cited by 1
“Mutations are processed to neoantigens and presented by major histocompatibility complex (MHC) proteins to T cells including melanoma.(4) The association between HLA class II expression and TMB was analyzed using 116 melanoma specimens from 4 cohorts (DFCI-Neovax18, MGH3, Checkmate 064, Checkmate 038), indicating that…”
Method
A Perspective Review of Cancer Therapy (Part I): Immunotherapy, Gene Therapy, and Nanotechnology
Pajuelo, A. (2023) · Science Insights · doi:10.15354/si.23.re833 · Cited by 1
“Occasionally, tumors with a substantial mutational burden, which signifies a greater number of mutations in the tumor genome, have demonstrated superior response rates to immunotherapy (32).”
Background
ZFC3H1 as an Indicator of Poor Prognosis in Hepatocellular Carcinoma: Bioinformatic Analysis and Experimental Verification
Zhao, J., Wang, C., Wu, R., Fang, Z., Dong, R., Zhou, J., & Hu, Z. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073317938240729055626 · Cited by 1
Pan-cancer analysis of m1A writer gene RRP8: implications for immune infiltration and prognosis in human cancers
Huang, Z., Yoo, K. H., Li, D., Yu, Q., Ye, L., & Wei, W. (2024) · Discover Oncology · doi:10.1007/s12672-024-01299-0 · Cited by 1
Identification of Cuproptosis-Related Genes for Molecular Subtyping: Predicting Prognostic and Therapeutic Response in Glioma
Xia, X., Huang, X., Wu, L., Xu, P., & Li, P. (2024) · OncoTargets and Therapy · doi:10.2147/ott.s481443 · Cited by 1
Nodal Yield From Neck Dissection Predicts the Anti‐Tumor Immune Response in Head and Neck Cancers
Chen, S., Pyne, J. M., Liu, Y., Abraham, Y., Wen, Z., Palsgrove, D. N., Xiao, G., Truelson, J. M., Myers, L. L., Tillman, B. N., et al. (2024) · Head & Neck · doi:10.1002/hed.28006 · Cited by 1
Development of a coagulation‑related gene model for prognostication, immune response and treatment prediction in lung adenocarcinoma
Li, J., Gao, X., Lv, L., Huang, Y., Zhang, H., Sun, X., & Zhu, L. (2025) · Oncology Letters · doi:10.3892/ol.2025.15035 · Cited by 1
Predicting the Efficacy of Immune Checkpoint Inhibitors in Esophageal Cancer: Changes in Peripheral Blood Lymphocyte Subsets Before and After Immunotherapy
Cao, R., Jiao, P., Zhang, S., Li, J., & Liu, Q. (2025) · Cancer Management and Research · doi:10.2147/cmar.s503171 · Cited by 1
“12–14 Further, deficient mismatch repair (dMMR) occurs in only 4.35% of EC cases, making MSI a rarely reported factor in this cancer type.”
Influential
Neurogranin facilitates maintaining the immunosuppressive state of hepatocellular carcinoma by promoting TGF-β1 secretion
Ye, D., Zhang, Z., Yao, Y., Pan, B., Wu, H., Zhang, X., Wang, X., & Tang, N. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.143716 · Cited by 1
Ferroptosis-related gene signature-based subtype identification of triple-negative breast cancer to prioritize treatment strategies
Chen, Y., Huang, X., Wang, J., Hu, C., Zheng, Y., Wang, Y., Zheng, S., Ji, G., & You, Q. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1541119 · Cited by 1
“Higher TMB leads to higher TNB, increasing chances for T-cell recognition, and is clinically associated with better ICI therapy outcomes (33).”
Arginine methylation patterns in LUAD: defining prognostic subtypes and relevance to immunotherapy
Shen, Q., Yang, Y., Guan, M., & Li, H. (2025) · Discover Oncology · doi:10.1007/s12672-025-02549-5 · Cited by 1
“Studies have shown that high TMB usually produces more neoantigens, enhancing immune system recognition and anti-tumor response, and the higher the TMB level, the more likely immunotherapy benefits [35, 36].”
Concurrent SMARCA4-deficient and poorly differentiated adenocarcinomas in separate lung lobes: a case report and literature review
Wang, L., Wu, Y., Hu, L., & Wang, G. (2025) · World Journal of Surgical Oncology · doi:10.1186/s12957-025-03839-6 · Cited by 1
“Nonetheless, studies have shown a significant association between the use of immune checkpoint inhibitors (ICIs) and improved overall outcomes in NSCLC with SMARCA4 mutations [29, 33, 37, 38].”
Comprehensive multi-omics pan-cancer analysis revealed EGFLAM as a potential prognostic and immune infiltration-associated biomarker
Yang, J., Xu, W., Wang, S., Zhu, Y., Feng, Y., Li, D., & Chen, J. (2025) · BMC Cancer · doi:10.1186/s12885-025-14519-9 · Cited by 1
The molecular subtype based on cell cycle-related gene signature predicts the prognosis and chemotherapy and immunotherapy response in gastric cancer
Su, R., Chen, J., Dai, C., Yin, S., Chen, H., Sun, X., Fang, Z., Zhang, C., Chen, J., & Gu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-01472-7 · Cited by 1
“In other words, the production new tumor-associated antigens (TAAs) depend on mutation of genes, which mean that high TMB indicates a stronger immunogenicity of cancer cells theoretically 43,46,47 .”
The oncogenic role of SPOCK1 in lung carcinoma by promoting immune evasion and its related mechanisms
Lv, G., Chen, J., Wei, D., Zhang, W., Xie, W., & Yang, S. (2025) · Cytotechnology · doi:10.1007/s10616-025-00804-9 · Cited by 1
“Tumor mutational burden (TMB) reflects the quantity of mutations in cancer, and an increase in its level is related to the enhanced the efficacy of immune checkpoint inhibitors (Jardim et al. 2021).”
PGLS as an immune and prognostic biomarker: from pan-cancer analysis to validation
Lei, S., Hu, S., & Wang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03108-8 · Cited by 1
“Tumour mutational burden (TMB) was significantly correlated with immunotherapy sensitivity [28], with PGLS expression displaying a positive correlation with TMB in KIRC and ACC, and a negative correlation with TMB in COAD and CHOL (Fig.”
Evolving treatment strategies in meningioma: from traditional approaches to emerging therapies
Patel, T. D., Henna, F., Ibrahim, H. Y., Maloth, A. K., Rehman, A. U., Kazmi, S. R. Z., Hussain, A., & Hanani, C. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000003556 · Cited by 1
“The aim of this study is to assess whether this combination may increase therapeutic efficacy [ 49 ] .”
Immunogenomic profiles of HIV-associated classic Hodgkin lymphoma from Malawi
Beck, S., Cowell, A., Roush, S. M., Mponda, M., Kasonkanji, E., Tomoka, T., Keene, S. A., Volaric, A. K., Painschab, M., Westmoreland, K. D., et al. (2025) · Blood Global Hematology · doi:10.1016/j.bglo.2025.100020 · Cited by 1
“44,45 46–48 Microdissection and flow sorting techniques provide a more detailed, in-depth view of the mutational profile of HRS cells compared with bulk sequencing, but at a much higher cost that cannot be utilized globally and/or clinically.”
Quality-of-life scale machine learning approach to predict immunotherapy response in patients with advanced non-small cell lung cancer
Shen, J., Ma, J., Chen, S., Jin, S., Xu, J., Li, Q., Zhang, C., Tian, X., Chen, X., Wang, H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1600265 · Cited by 1
Epigenetically regulated ZCCHC9 plays a pro-tumorigenic role in glioma based on a multi-omics analysis
Lin, Z., Zhang, J., Li, Y., Wang, W., Xi, W., Jia, L., Wang, T., & Chen, X. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.146603 · Cited by 1
Potential of APOBEC3B as a therapeutic target and its role in bladder cancer onset and progression
He, Z., Chen, G., Gu, J., Wang, W., Li, H., Tan, Z., Wang, H., Wang, J., Ding, M., & Huang, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03033-0 · Cited by 1
“Moreover, TMB reflects the mutation burden of cancer, which can produce novel antigens presented to T cells via major histocompatibility complex proteins [40].”
A comprehensive immune cycle enhancement strategy for alternative splicing-mediated endogenous Tumor neoantigens generation and delivery
Wang, L., Liu, Y., Wang, Z., Liu, J., Yan, Z., & Liu, X. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102231 · Cited by 1
“Research has indicated that even in tumors with a high mutational burden such as osteosarcoma, numerous factors hinder the efficient transformation of these mutations into immunogenic neoantigens capable of eliciting robust immune responses [14].”
Influential
Novel Metabolic‐Prognostic Integration Reveals TCF21‐Mediated Mitochondrial Regulation in Endometrial Cancer
Guo, C., Zheng, J., Lin, X., Ye, X. Z., Jiang, X., & Sun, Y. (2025) · Molecular Carcinogenesis · doi:10.1002/mc.70041 · Cited by 1
Identification of immunological and prognostic value of SHROOM2 in pan-cancer and experimental verification of its role in promoting malignant phenotypes in breast cancer
Wang, Y., Ren, Y., Zheng, X., Wang, Y., Wang, H., Zhang, X., & Li, S. (2025) · PeerJ · doi:10.7717/peerj.20051 · Cited by 1
“TMB quantifies the number of nonsynonymous somatic mutations per megabase (Mb) in a tumor cell genome and is a key predictor of immunotherapy efficacy ( Jardim et al., 2021 ).”
A disulfidptosis‐related gene signature predicts prognosis and immune‐metabolic landscape in multiple myeloma
Wang, L., Wang, J., Wang, Y., Niu, T., & Zhao, A. (2025) · British Journal of Haematology · doi:10.1111/bjh.70189 · Cited by 1
“35,36 Together, these findings define the high-risk subtype by aggressive features including hyperproliferation, inflammatory signalling and transcriptional dysregulation.”
A novel disulfidptosis-related mRNA signature predicts prognosis and therapeutic response in lung squamous cell carcinoma
Bai, W., Jiang, N., Deng, Y., Tang, X., Zhang, F., Niu, S., Yao, Y., Zhou, Y., Chen, K., Li, L., et al. (2025) · BMC Pulmonary Medicine · doi:10.1186/s12890-025-03920-6 · Cited by 1
“It is a biomarker that can serve as a predictive factor for Studies have shown that patients with high TMB tend to have better prognoses [20, 21].”
LRP1b Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial
Armstrong, A. J., Dietz, H., Balli, D., Geese, W. J., Duan, C., Hung, Y.-H., Ip, V., Li, G., Graf, R. P., & Ready, N. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0952 · Cited by 1
Bioinformatics analysis of the expression of TRIM31 mRNA and protein in pan-cancer tissues and their prognostic relevance
Mei, Y., Chen, Y., Zhou, Y., & Jiang, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-19932-5 · Cited by 1
“TMB and MSI are significant biomarkers that serve as predictors of the immunotherapy response 45–47 .”
Case Report: Two cases of long-term survival in advanced pancreatic cancer patients following treatment with KRAS G12C inhibitors
Aslani, S., McKay, O., Lipton, L. R., Ganju, V., & Croagh, D. G. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1691760 · Cited by 1
“Her genomic pro ﬁ le revealed a low TMB and stable MSI, suggesting limited responsiveness to immunotherapy (18).”
Predicting Immunotherapy Outcomes in NSCLC Using RNA and Pathology from Multicenter Clinical Trials
Wang, Z., Fang, Y., Huang, X., Ma, G., Mao, Q., Lu, X., Rong, G., Yu, Y., Wang, Y., Huang, Z., et al. (2025) · Advanced Science · doi:10.1002/advs.202502037 · Cited by 1
Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation
Pei, J., Fan, J., Liao, Y., Li, M., Bai, X., Wang, Y., Zhang, H., Kong, Y., & wang, G. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03253-5 · Cited by 1
“These ﬁ ndings offer a theoretical foundation for exploring the pathogenesis, clinical identi ﬁ cation, and associated therapies for EC.”
Development and validation of a novel nerve-related prognostic model for gastric cancer based on bulk and single-cell RNA sequencing data
Qiu, L., Yao, S., Yang, Z., Zhou, Z., Yang, F., Zhu, X., Liu, F., Gong, Y., Li, S., Liu, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15202-9 · Cited by 1
“Tumors with higher tumor mutation load (TMB) were considered more prone to present higher levels of neo-antigen, which can help the immune system recognize tumor features [31].”
Unveiling oncogene-induced senescence: a new frontier in prostate cancer prognosis and therapy
Peng, Y., Qiu, X., Cai, J., Li, Y., & Wei, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-03893-2 · Cited by 2
Comprehensive clinico-genomic analysis of pancreatic ductal adenocarcinoma: Overcoming biases and limitations
Jung, K., Lee, J.-C., Kim, J.-H., Na, H. Y., Kim, J. H., Youn, Y., Para, N., Kim, J., & Hwang, J. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218176 · Cited by 1
PGK1 is a prognostic molecule and silencing PGK1 inhibits the growth in breast cancer cells
Yang, Z., & Han, Y. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102396 · Cited by 1
Case Report: SMARCA4-deficient NSCLC with brain metastasis harboring co-mutations in chromatin remodeling and DNA damage repair pathways
Song, J., Yang, S., & Lei, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1683301 · Cited by 1
Pan-cancer multi-omics analysis of CCT4 in tumor progression and cancer immunity, with focus on lung adenocarcinoma
Wu, Y., Wu, Z., Wen, J., & Zhou, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1714837 · Cited by 1
Abscopal Effect Induced by LAG-3/PD-1 Inhibition and Radiation Therapy in Metastatic Acral Melanoma: A Case Report
Kim, S., Stull, W., Ishihara, D., Sabatelli, F., & Clark, J. I. (2025) · Case Reports in Oncology · doi:10.1159/000549890 · Cited by 1
“…which is associated with ultraviolet radiation-induced DNA damage and a resulting high tumor mutational burden (TMB), AM typically lacks ultraviolet-signature mutations, exhibits low TMB, and is characterized by reduced immunogenicity and a highly immunosuppressive tumor microenvironment [4, 5].”
Genomic divergence between matched primary and metastatic tumors across cancer types: a pan-cancer analysis of 5,692 samples
Ergün, Y. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2601769 · Cited by 1
Comprehensive analysis of BIRC5: from pan-cancer analysis to experimental validation
Liao, G., Qian, J., Wei, S., Yan, X., Liu, Q. L., Huang, Q., Lin, Y., Xu, G., Zheng, B., Chen, C., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-15184-8 · Cited by 1
“Some investigations have indicated that tumors with higher TMB and MSI are linked to improved immune response [54– 56].”
Deciphering Resistance: Beyond the Androgen Paradigm; Report From the 2025 Coffey‐Holden Prostate Cancer Academy Meeting
Stoyanova, T. I., Priceman, S. J., Ross, A. E., Tran, P. T., McKay, R. R., Pienta, K. J., Soule, H. R., & Miyahira, A. K. (2025) · The Prostate · doi:10.1002/pros.70102 · Cited by 1
Genomic alterations linked to recurrence risk in high-grade serous ovarian cancer revealed by deep targeted sequencing
Park, Y.-H., Park, S.-W., Kim, J. H., Lee, Y., Cho, H., Park, I.-H., Han, M.-R., & Kim, J.-H. (2025) · Scientific Reports · doi:10.1038/s41598-025-26481-4 · Cited by 1
“It has been identified as a factor that determines the response to immunotherapy in various cancers 31 .”
Exploring the role of CCT7 in prognosis, cell cycle regulation, and immune microenvironment remodeling of lung adenocarcinoma based on multi-omics datasets and functional experiments
Deng, L., Ruan, J., & Li, Y. (2025) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2025.130896 · Cited by 1
Beyond tumor mutation burden: tumor neoantigen burden as a superior prognostic biomarker in resected gastric cancer
Lu, T., Cao, J., Liu, P., Pan, X., Shen, Y., Wang, J., Chen, Z., Liu, Y., Zhang, F., Zhang, H., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722895 · Cited by 1
“Without an assessment of immunogenicity, TMB might be an imperfect surrogate biomarker for neoantigen-based immunotherapy (18).”
Survival and multi-omics analysis of immunotherapy-based conversion treatment for initially unresectable gastric cancer
Li, S., Qian, X., Yu, W., Liu, Z., Cui, X., Wei, M., Shi, D., Zhao, W., Song, X., Zhang, D., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1753749 · Cited by 1
Concomitant use of H1 antihistamines improves survival outcomes in cancer patients on immune checkpoint inhibitor therapy: a systematic review and meta-analysis
de Moraes, F. C. A., Wagner, P. H. D. S., Rd, H., Burbano, R. M. R., & Hirata, M. H. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2617952 · Cited by 1
“An important consideration is that TME composition and tumor mutational burden (TMB) may reflect different immunotherapy outcomes [68].”
Comparative Efficacy and Safety of Bispecific T-Cell Engagers (BiTEs) Versus Immune Checkpoint Inhibitors (ICIs) in Hematologic Malignancies
Qureshi, Z. A., Jamil, A. R., Samsuddoha, K., & Kahlon, N. (2026) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001295 · Cited by 1
Intrapatient variation in PD-L1 expression and tumor mutational burden and implications for outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Li, G., Xu, J., Tian, X., Xiao, J., Long, J., Chen, Y., Shen, W., & Zhao, S. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013328 · Cited by 1
“5 19 When tumor cells attempt to escape such immune responses, they may simultaneously regulate PD-L1 expression and TMB.”
Aberrant SUMOylation Restricts the Targetable Cancer Immunopeptidome
Demel, U. M., Meurer, A., Zaghla, B. K. Q., Atay, B., Steiert, D., Hummel, L. V., Isaakidis, K., Zang, C., Korenkov, M., Schielin, M., et al. (2026) · Advanced Science · doi:10.1002/advs.202511449 · Cited by 1
“Remarkably, high TMB is associated with increased expression of tumor-specific neoantigens, overall potentiating the patient’s therapeutic response to ICB [ 8 ].”
Association of the neutrophil to lymphocyte ratio and clinical outcomes in cancers: a systematic review and meta-analysis
Zhu, S., Li, W., Zhang, H., Lin, Y. E., & Chen, Z. (2026) · Biomarkers in Medicine · doi:10.1080/17520363.2026.2625220 · Cited by 2
Lactylation-related gene signature as a prognostic biomarker for neuroblastoma: insights into tumor progression and immune modulation
Zhu, J., Luo, M., Yuan, L., He, J., Wang, Z., Deng, Q., Wang, J., Jin, M., Liu, G., Liang, H., et al. (2026) · Cell & Bioscience · doi:10.1186/s13578-026-01538-7 · Cited by 1
“5D) [32].”
Predictive Value of Insertion/Deletion Rate in Patients With Gastric Cancer Treated With Nivolumab Plus Chemotherapy
Kim, H., Lee, H., Lee, S., Lee, Y., Hyung, J., Moon, M., Shin, J., Park, Y. S., & Ryu, M. (2026) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2026.26.e14 · Cited by 1
“Mechanistically, Indels frequently cause frameshift mutations, which generate more immunogenic neoantigens than SNVs [14,19,20].”
Overcoming Immunotherapy Resistance in Small-Cell Lung Cancer
Canale, M., Suzzi, F., Verlicchi, A., Citarella, F., Delmonte, A., & Ulivi, P. (2026) · Biology · doi:10.3390/biology15040356 · Cited by 1
“The influence of finding an optimal cut-off and the variability of different genomic tests limit the potential of TMB as a reliable predictor of immunotherapy benefit [9].”
Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702)
Kuroda, S., Tazawa, H., Hashimoto, M., Kanaya, N., Kakiuchi, Y., Kagawa, S., Urata, Y., & Fujiwara, T. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-02991-7 · Cited by 1
“Furthermore, the intrinsically low tumor mutation burden (TMB) and downregulation of major histocompatibility complex (MHC) molecules reduce the immunogenicity of pancreatic cancer, allowing tumors to evade immune surveillance [34].”
Tumor Mutational Burden Shapes Success and Resistance in Cancer Immunotherapy
Aguadé‐Gorgorió, G. (2026) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2026.112421 · Cited by 1
Analysing cell death patterns to predict outcomes and treatment options in patients with high-grade serous ovarian carcinoma
Li, X.-N., Wei, L. L., Wang, S.-Y., Yu, Y.-K., Hazaisihan, Y., Gao, X., Huang, L.-J., Meng, Q.-H., Zheng, Y.-Q., & Jia, W. (2026) · Scientific Reports · doi:10.1038/s41598-026-42628-3 · Cited by 1
Biomarker-guided immunotherapy in gastric cancer: current insights and future perspectives
Mulet, M. T., Rodríguez, J. V., Terán, E., Piñol, M., Vilardell, F., Iglesias, M., Hierro, C., Calvo, M., Matías‐Guiu, X., Salud, A., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103124 · Cited by 1
Adenosine Pathway Activation Defines Genetically Linked Immunosuppressive Subtypes in Solid Tumor Brain Metastases
Bauer, A., Arndt, A., Reichenbach, L. B., Gebauer, N., Müller, M. M., Neumann, C., Schulz, C., Steinestel, K., Heller, R. A., Chteinberg, E., et al. (2026) · Cancers · doi:10.3390/cancers18071087 · Cited by 1
“…immune escape in brain metastases may be dominated by microenvironmental and metabolic suppression programs that can operate independently of neoantigen burden, consistent with current perspectives questioning the predictive value of TMB in immunologically constrained metastatic niches [35,36].”
Baseline tumor burden and outcomes in patients with rare cancers treated with immunotherapy (Southwest Oncology Group trial S1609)
Swiecicki, P. L., Othus, M. K. D., Patel, S. P., Chae, Y. K., & Kurzrock, R. (2026) · Cancer · doi:10.1002/cncr.70374 · Cited by 1
“19,20 Imaging is a tool that is broadly used and thus is amenable to analysis in relation to outcome.”
Self-citation
LPCAT1 and MRPL9 Promote Hepatocellular Carcinoma Progression via AKT Phosphorylation and Define a Mitochondrial Prognostic Model
Yang, H., Zhu, Z., Zhu, H., Li, N., Zheng, S., Hu, L., Wu, Z., & Shi, Y. (2026) · Cancers · doi:10.3390/cancers18071144 · Cited by 1
“Previous studies have demonstrated that elevated TMB leads to the generation of more neoantigens, which are processed and presented by major histocompatibility complex (MHC) molecules to T cells, thereby eliciting an anti-tumor immune response [37].”
Immunotherapy in Thyroid Cancer: Current Strategies and Challenges
Zhang, Q. P., Wang, F., Ma, W., Liu, N., Lu, Y., & Zhang, P. X. (2026) · Cancer Medicine · doi:10.1002/cam4.71742 · Cited by 1
“A low TMB implies fewer neoantigens produced by the tumor, and the absence of tumor-specific antigens may hinder the effective activation of immune responses by anti- PD-1/PD-L1 therapy [82, 83].”
Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review
Calabrò, C., Palma, G. D., Gheit, T., Iacovelli, S., Mastrandrea, G., Rizzo, A., & Palermo, L. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2665455 · Cited by 1
“To escape immune elimination, cancers exploit checkpoints that suppress T-cell activity [32].”
Deciphering spatial-temporal mechanisms of PD-1 blockade resistance via biologically informed machine learning
He, L., Zhao, M., Hu, Y., Chen, L., & Zheng, B. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116797 · Cited by 1
Transcriptomic profiling identifies immunotherapy-responsive phenotypes in microsatellite-stable metastatic colorectal cancer
Konečný, T., Zadirako, N., Grigoryan, A., Tamazyan, M., Mnatsakanyan, S., Stepanyan, L., Loeffler‐Wirth, H., Bourdelais, S., Mednick, G., Delepine, C., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03861-2 · Cited by 1
“These ﬁ ndings support the hypothesis that tumor heterogeneity is shaped by both the developmental state of epithelial tumor cells and their dynamic interactions with the TME and its varying composition, although the ATRX loss, CIMP status, and copy-number changes were inferred from…”
Microbiome–Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers
Kawashima, A., Jingushi, K., Saito, T., Uemura, T., Yamamoto, A., Sassi, N., Horitani, H., Inoguchi, S., Horibe, Y., Ishizuya, Y., et al. (2026) · Cancer Science · doi:10.1111/cas.70448 · Cited by 1
“Tumor-intrinsic markers such as PD-L1 expression, tumor mutational burden, and related gene-expression features can be informative, but they do not fully explain the heterogeneity of clinical benefit observed across patients [59, 60].”
Radiotherapy-Associated Systemic Antitumor Responses Beyond the Classical Abscopal Paradigm
Dotsu, Y., Akagi, K., Honda, N., Matsuo, M., Taniguchi, H., Takemoto, S., & Mukae, H. (2026) · Cancers · doi:10.3390/cancers18132098 · Cited by 1
“Similarly, ctDNA kinetics and TCR repertoire changes are promising tools for monitoring tumor burden and adaptive immune activation, but their role in confirming radiation-associated systemic immune responses remains to be explored [73,74].”
Real‐World Response of Cemiplimab Immunotherapy for Treating Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma in a Tertiary UK Oncology Centre
Umar, S., Shahid, Z., O’Cathail, M., & Sivanandan, A. (2026) · Journal of Skin Cancer · doi:10.1155/jskc/8993856 · Cited by 1
Immune checkpoints and immunoregulation in metabolic diseases and cancers: pathological mechanisms and therapeutic potential
Xiang, M., Liu, S., Xiao, D., & Tao, Y. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02810-5 · Cited by 1
“188 TMB quanti ﬁ es the mutation load in tumors and is a predictive biomarker for response to immunotherapy.”
Expression Patterns of Necroptosis-Related Genes: Predicting Prognosis and Immunotherapeutic Effects in Cutaneous Melanoma
Dong, D., Wang, W., Wang, H., Chen, L., & Liu, T. (2022) · Journal of Oncology · doi:10.1155/2022/5722599 · Cited by 1
CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data
Li, F., Dong, K., Zhang, C., Wang, J., Tang, Y., Xue, K., Zheng, X., Song, K., Zhang, X., Li, M., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03414-6 · Cited by 1
Development and validation of a novel defined mutation classifier based on Lasso logistic regression for predicting the overall survival of immune checkpoint inhibitor therapy in renal cell carcinoma
Chen, M., Li, P., Yao, H., Liu, F., Fu, L., Wang, Y., Zhu, J., Xu, Q., Liang, H., Zhou, Y., et al. (2023) · Translational Andrology and Urology · doi:10.21037/tau-23-21 · Cited by 1
“And nonsynonymous gene mutation results in more neo-antigens, thus increasing chances for T cell recognition, and indicating better ICI outcomes (17).”
Evolution of Biomarkers and Treatment Outcomes of Immunotherapy in Lung Cancer
Kaler, A. K., Maskomani, S., Ritambhara, Kavyashree, K., Vadera, V., Choudhary, V., Shaikh, I. N., Goyle, S., & Mistry, R. (2023) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-023-00047-w · Cited by 1
“However, the combination of both factors would enhance the predictive power significantly [51, 52].”
A novel coagulation-related lncRNA predicts the prognosis and immune of clear cell renal cell carcinoma
Wu, W.-S., Chang, F., Zhang, J., Tang, S., Lv, Z., & Chen, F. (2023) · Scientific Reports · doi:10.1038/s41598-023-43065-2 · Cited by 1
Stroma-associated FSTL3 is a factor of calcium channel-derived tumor fibrosis
Li, J.-P., Liu, Y., Yin, Y. H., Li, R., Huang, W., & Zou, X. (2023) · Scientific Reports · doi:10.1038/s41598-023-48574-8 · Cited by 1
“Further calculations showed that FSTL3 was independent of MSI but inversely associated with TMB (r = − 0.244, P 0.001, Fig.”
MethodInfluential
Identification of immune-related gene signature for non-small cell lung cancer patients with immune checkpoint inhibitors
Li, W., Han, C., Cai, C., Wu, J., Chen, J., & Su, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26974 · Cited by 1
Prognostic value and immune landscapes of anoikis-associated lncRNAs in lung adenocarcinoma
Wu, B. C., Zhang, X., Feng, N., Guo, Z., Gao, L., Wan, Z., & Zhang, W. (2024) · Aging · doi:10.18632/aging.205481 · Cited by 1
“Furthermore, TMB is usually employed as a predictive indicator for immunotherapy in urothelial, lung and head and neck squamous cell cancers [31].”
Background

Authors: Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R.
Affiliations: Hospital Sírio-Libanês (BR)
University of California San Diego (US)
Corresponding author: Kurzrock, Razelle
ORCID: Jardim, Denis L.
Goodman, Aaron
Kurzrock, Razelle
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2021-02
Volume: 39
Issue: 2
Pages: 154-173
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.10.001
PMC: PMC7878292
OpenAlex: W3097803258
Cited by: 1,192
References: 151
Citations by year: 2026: 134 · 2025: 263 · 2024: 294 · 2023: 276 · 2022: 171 · 2021: 53
FWCI: 13.60
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 372 d)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: Astellas Pharma US
National Cancer Institute (P30 CA023100)
Janssen Pharmaceuticals
AstraZeneca
Bristol-Myers Squibb
Genentech
Roche
EMD Serono
Pfizer
Meso Scale Diagnostics
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: tumor mutational burden, immunotherapy biomarkers, immune checkpoint inhibitors, neoantigens, MHC class I antigen presentation, T cell receptor repertoire, cancer immunotherapy response prediction
MeSH terms: Immune Checkpoint Inhibitors, Humans, Immunotherapy, Major Histocompatibility Complex, Mutation, Neoplasms, T-Lymphocytes, Biomarkers, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks